Advertisement

Topics

Mylan, U.S. finalize $465 million EpiPen settlement

12:57 EDT 17 Aug 2017 | Topix

The U.S. Attorney's Office in Massachusetts revealed the accord on Thursday, 10 months after Mylan said it reached a deal resolving claims it misclassified the EpiPen as a generic rather than a branded product to avoid paying rebates owed to Medicaid. "Taxpayers rightly expect companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules," Acting U.S. Attorney William Weinreb said in a statement.

Original Article: Mylan, U.S. finalize $465 million EpiPen settlement

NEXT ARTICLE

More From BioPortfolio on "Mylan, U.S. finalize $465 million EpiPen settlement"

Advertisement
Quick Search
Advertisement
Advertisement